[go: up one dir, main page]

NZ756367B2 - Methods of treating schizophrenia - Google Patents

Methods of treating schizophrenia Download PDF

Info

Publication number
NZ756367B2
NZ756367B2 NZ756367A NZ75636718A NZ756367B2 NZ 756367 B2 NZ756367 B2 NZ 756367B2 NZ 756367 A NZ756367 A NZ 756367A NZ 75636718 A NZ75636718 A NZ 75636718A NZ 756367 B2 NZ756367 B2 NZ 756367B2
Authority
NZ
New Zealand
Prior art keywords
effective amount
amount
therapeutically effective
pharmaceutically acceptable
subject
Prior art date
Application number
NZ756367A
Other versions
NZ756367A (en
Inventor
Seth Hopkins
Kenneth Koblan
Antony Loebel
Ajay Ogirala
Original Assignee
Sunovion Pharmaceuticals Inc
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Priority claimed from PCT/US2018/000078 external-priority patent/WO2018151861A1/en
Publication of NZ756367A publication Critical patent/NZ756367A/en
Publication of NZ756367B2 publication Critical patent/NZ756367B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Abstract

Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

Claims (10)

WHAT WE CLAIM IS:
1. The use of the compound O S or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of negative symptoms of schizophrenia in a subject in need thereof.
2. The use of claim 1, wherein the treatment comprises stering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof.
3. The use of claim 2, wherein the therapeutically ive amount is an amount between about 10 mg and about 40 mg.
4. The use of claim 2, wherein the therapeutically effective amount is an amount between about 40 mg and about 70 mg.
5. The use of claim 2, wherein the therapeutically effective amount is an amount between about 70 mg and about 100 mg.
6. The use of claim 2, wherein the therapeutically effective amount is an amount between about 100 mg and about 130 mg.
7. The use of any one of claims 2-6, n the eutically effective amount is provided as a once daily dose.
8. The use of any one of claims 1 to 7, wherein the treatment ses administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the compound O S or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
9. The use of claim 1, wherein the treatment comprises administering a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof to said subject for four weeks, wherein the subject ences a decrease in ve Positive and Negative me Scale (PANSS) score after four weeks of administration.
10. The use of claim 9, wherein the ve PANSS score is determined by negative PANSS factors N01 Blunted Affect, N02 Emotional Withdrawal, N03 Poor Rapport, N04 e/Apathetic Social Withdrawal, N05 Difficulty in
NZ756367A 2018-02-16 Methods of treating schizophrenia NZ756367B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459784P 2017-02-16 2017-02-16
PCT/US2018/000078 WO2018151861A1 (en) 2017-02-16 2018-02-16 Methods of treating schizophrenia

Publications (2)

Publication Number Publication Date
NZ756367A NZ756367A (en) 2024-12-20
NZ756367B2 true NZ756367B2 (en) 2025-03-21

Family

ID=

Similar Documents

Publication Publication Date Title
FI3849534T3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
Chen et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial
JP6159084B2 (en) Composition containing berberine or an analogue thereof for treating skin diseases associated with rosacea or blush
RU2016130056A (en) METHODS FOR TREATING SKIN INFECTION BY ADMINISTRATION OF AN IL-4R ANTAGONIST
IL300151A (en) Combinations for cancer treatment
EA202190115A1 (en) FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS FOR THEIR PREPARATION
NZ714963A (en) Compositions and methods for treating anemia
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
EA200801967A1 (en) DOSED DOSAGE FORM ON THE BASIS OF CYCLOGEXANE POLYOL (VARIANTS), MAKING THE TREATMENT, MEANS OF ITS TREATMENT, A METHOD OF TREATING THE DISEASE OF THE ALTSHEIMER WITH ITS HELP AND CYCLOGEXANE POLYOUS AS A QUALITY, ITSELF COURSE
RU2010142456A (en) SYNERGIC COMBINATIONS OF 5'-METHYLTHIOADENOSINE
Nagappa et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis
FI3970707T3 (en) Use of cannabidivarin in the treatment of negative symptoms in schizophrenia
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
RU2010138650A (en) COMBINATION INCLUDING PACLITAXEL FOR TREATMENT OF OVARIAN CANCER
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
NZ756367B2 (en) Methods of treating schizophrenia
US20240066035A1 (en) Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B
NZ756367A (en) Methods of treating schizophrenia
FI3359572T3 (en) METHOD FOR TREATING MULTIPLE SCLEROSIS
EA201170970A1 (en) DEFERIPRON APPLICATION FOR TREATMENT AND PREVENTION OF EYE DISEASES ASSOCIATED WITH IRON
CN101605541A (en) Pyrrolo[1,2-a]imidazole diones effective in the treatment of chemotherapeutic drug-induced peripheral neurotoxicity
US20240238256A1 (en) Nitazoxanide in the treatment of sepsis
US20240358726A1 (en) Specific therapeutic medical marijuana doses for stress and pain
UY38137A (en) A SOLID PHARMACEUTICAL SOLID ORAL DOSAGE FORM
RU2016147455A (en) METHOD FOR TREATMENT OF SKIN MANIFESTATIONS OF SCLERODERMA